Full-Time

Associate Director

Purification Process Development

Evotec

Evotec

1,001-5,000 employees

Global drug-discovery services via partnerships

Compensation Overview

$154k - $180k/yr

+ Discretionary Annual Bonus

Redmond, WA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Data Analysis
Requirements
  • BS/MS in Engineering, Biochemistry, Biology, or related field with 15+ years of experience or Ph.D. in Engineering, Biochemistry, Biology, or related field with 9+ years of experience.
  • Expertise in continuous purification technology development, transfer to cGMP manufacturing plants, and authoring CMC sections of regulatory filings.
  • Experience with commercial process development, process characterization, and validation.
  • Expertise in design of experiments (DOE) and statistical analysis.
  • Experience in training, mentoring, and supervising team members as well as leading purification development teams for external client projects and collaborations and internal technology development initiatives.
Responsibilities
  • Leading a purification department with a diverse group of scientists encompassing all aspects of purification process development, characterization, and validation as well as technology transfer to cGMP manufacturing for hybrid and end-to-end continuous processes.
  • Leading highly complex projects and investigations by integrating deep knowledge of purification process development and broad knowledge of project work with knowledge of multiple functional areas outside of purification.
  • Collaborating across the organization to accelerate clinical development timelines while reducing development costs.
  • Driving technology development for process intensification and continuous manufacturing to reduce manufacturing costs and footprint through improvements in culture productivity, control of product quality, and data management while working with vendors and external partners as well as influencing the biologics industry.
  • Serving as a Project Team Lead within the process development organization to execute on client projects that involve multiple functional areas and the full range of regulatory stages.
  • Serving as an internal technical resource for cGMP manufacturing and Process Design as well as a resource and subject matter expert for external clients and partners for purification processes (small scale models, process transfer, and scale up) and authoring CMC regulatory sections.
  • Clearly and effectively communicating scientific information, experimental plans, and data to internal project teams, cross-functional area teams, senior management, external clients, vendors, and technology development collaborators as well as the external scientific community such as regulatory agencies, review boards, publications, and conferences.
  • Managing staff, training, capital resources, and planning within the department while supporting multiple client projects at various stages of process development and characterization.
  • Other tasks as assigned.
Desired Qualifications
  • Experience with high throughput methods (e.g. HT assays, robotics such as TECAN and Robo-Columns, and lab automation).
  • Experience analyzing data in tools such as JMP, R, or Python.
  • Experience working in a cGMP or clean room setting (this job is non-GMP but knowledge of GMP is helpful for process/tech transfer activities).
  • Experience working in retail, service industry, or other environments that require physical work and positive attitude.

Evotec provides R&D services for drug discovery and development through strategic partnerships with pharma, biotech, and academic institutions, using platforms like iPSCs and machine learning. It conducts experiments and data analysis with iPSC-derived cellular models and AI/ML tools to identify and optimize drug candidates, often incorporating patient-derived materials for precision medicine, offering end-to-end discovery through clinical development under contract. The company differentiates itself with an integrated, data-driven, cell-based platform within a collaboration model and a focus on precision medicine, biologics, and gene therapy, with a strong US and European presence. Its goal is to bring new and better medicines to patients faster and at lower cost by making drug discovery and development more efficient through partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hamburg, Germany

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Just-Evotec Biologics revenue surged 39.8% to €259.4M in 2025.
  • Sandoz $650M deal and $300M Toulouse sale boost cash inflows.
  • Horizon plan delivers €75M savings by 2027 via site optimizations.

What critics are saying

  • Sandoz divests Toulouse J.POD, eroding biologics manufacturing capacity.
  • WuXi AppTec undercuts pricing by 20-30% post-HSR clearance May 2026.
  • Horizon fails, breaches €116.1M bonds covenants by mid-2027.

What makes Evotec unique

  • J.POD Toulouse employs autonomous cleanroom PODs for continuous bioprocessing.
  • PanOmics and iPSC platforms integrate AI for precision drug discovery.
  • INDiGO bundles workflows from candidate to IND with in-house toxicology.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Evotec who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Unlimited Paid Time Off

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 8th, 2026
Evotec delivers $67M cost savings and $650M Sandoz deal amid 1.1% revenue decline

Evotec SE reported mixed Q4 2025 results, with group revenue increasing 14.5% to €253.3 million, though full-year revenue fell 1.1% to €788.4 million. Adjusted group EBITDA for Q4 rose 103.6% to €58 million, whilst full-year EBITDA increased 81.9% to €41.1 million. The Just-Evotec Biologics segment achieved breakthrough growth, with Q4 revenue surging 104.2% and full-year revenue rising 39.8% to €259.4 million. The company secured a $650 million agreement with Sandoz and received multiple milestone payments from partnerships. Evotec delivered over €60 million in annualised cost savings and reduced capital expenditure by approximately 60%. The company is implementing its Horizon transformation programme, expected to deliver €75 million in structural savings by end-2027, though this involves closing four sites and eliminating 800 positions.

The Associated Press
Apr 7th, 2026
Evotec nominates Dieter Weinand as supervisory board chairman to drive commercial execution

Evotec has nominated Dieter Weinand as chairman of its supervisory board, pending approval at the 11 June 2026 annual general meeting. Weinand will succeed Prof. Dr Iris Löw-Friedrich, whose term concludes at the meeting as part of the company's planned succession process. Weinand brings over 30 years of pharmaceutical industry experience, having served as president, CEO and chairman of Bayer Pharmaceuticals and held senior roles at Pfizer, Bristol Myers Squibb and Sanofi. He currently serves on several biotech boards and will reduce his board commitments to comply with German corporate governance requirements. The appointment aims to strengthen Evotec's commercial execution, strategic partnerships and profitability as the Hamburg-based life sciences company continues its transformation. Weinand holds an MS in pharmacology and toxicology from Long Island University.

The Associated Press
Apr 1st, 2026
Evotec appoints Dr. Ashiq H. Khan as chief commercial officer with $7B+ deal track record

Evotec has appointed Dr Ashiq H Khan as chief commercial officer. Dr Khan brings over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, having closed more than $7 billion in agreements across US, EU and APAC markets. In his new role, Dr Khan will build a globally integrated commercial organisation aligned with Evotec's scientific capabilities. He most recently served as chief business officer at Iktos and previously held leadership roles at Proteros and Schrödinger. Evotec is a life science company specialising in drug discovery and development, integrating AI-driven innovation with advanced technologies. The company employs over 4,800 experts across Europe and the US.

The Associated Press
Mar 19th, 2026
Evotec receives $10M milestone from Bristol Myers Squibb for kidney cancer drug trial

Evotec has received a $10 million milestone payment from Bristol Myers Squibb following the initiation of a Phase 1 clinical study for BMS-986506, a protein degradation treatment for advanced clear cell renal cell carcinoma, the most common form of kidney cancer. The study marks the first clinical milestone in the strategic protein degradation partnership between Evotec and Bristol Myers Squibb, which began in 2018 and was expanded in 2022. BMS-986506 is a cereblon E3 ligase modulator, or "molecular glue", developed using Evotec's multi-omics screening platform and AI-supported data analytics. The collaboration combines Evotec's PanOmics and PanHunter platforms with Bristol Myers Squibb's library of CELMoD agents to discover novel molecular glue degraders for oncology and other therapeutic areas.

Yahoo Finance
Mar 16th, 2026
Evotec unveils "Horizon" plan with $85M savings, 800 job cuts and 10-site footprint by 2028

Evotec has unveiled "Horizon", a transformation plan targeting €75 million in savings and guiding 2026 EBITDA to €0–40 million. The plan focuses on operational excellence, scientific leadership and commercial execution, building on earlier restructuring that delivered over €60 million in savings through end-2025. The company will reduce its global footprint from 14 sites to 10 over two years, resulting in approximately 800 position reductions. Evotec emphasises owned technology hubs in Toulouse and Verona as integrated discovery and preclinical development centres. Chief executive Christian Wojczewski said Evotec has upgraded commercial leadership and business development, with prospects increasing during the second half of 2025. The company previously streamlined its asset pipeline by 30% and reduced capital expenditure by 60% whilst strengthening its balance sheet.